Takeda Pharmaceutical Co. $TAK Shares Acquired by Bridgefront Capital LLC

Bridgefront Capital LLC lifted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 72.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 83,733 shares of the company’s stock after acquiring an additional 35,250 shares during the period. Bridgefront Capital LLC’s holdings in Takeda Pharmaceutical were worth $1,226,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Royal Bank of Canada grew its holdings in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares during the period. AQR Capital Management LLC raised its stake in Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock worth $2,911,000 after purchasing an additional 59,442 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares during the last quarter. Focus Partners Wealth boosted its holdings in Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after purchasing an additional 3,239 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical in the 2nd quarter valued at approximately $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $17.76 on Friday. The firm has a 50-day simple moving average of $17.44 and a two-hundred day simple moving average of $15.56. The stock has a market cap of $56.50 billion, a PE ratio of 73.98 and a beta of 0.01. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 29th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.55 by $0.40. The firm had revenue of $6.75 billion for the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. As a group, analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TAK. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday, January 31st. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Morgan Stanley started coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating for the company. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.